期刊文献+

尿核基质蛋白22诊断膀胱癌的临床评价 被引量:2

CLINICAL EVALUATION OF NUCLEAR MATRIX PROTEIN 22 (NMP22) IN URINE AS A MARKER FOR DIAGNOSING BLADDER TRANSITIONAL CELL CARCINOMA
暂未订购
导出
摘要 目的 :分析比较尿核基质蛋白 2 2 (NMP2 2 )检测与尿脱落细胞学检查诊断膀胱移行细胞癌的临床价值。方法 :对 12 6例临床怀疑膀胱癌的病人 ,在膀胱镜检查前留取新鲜自排尿 ,分别进行NMP2 2检测和脱落细胞学检查 ,比较 2种方法的敏感性、特异性和阳性预测值。结果 :12 6例中病理证实膀胱移行细胞癌 35例 ,其他疾病 91例。NMP2 2诊断膀胱癌敏感性 82 .9% ,与细胞学 (2 5 .7% )比较 ,差别有极显著性意义 (P <0 .0 1)。即使对浅表性膀胱癌 ,NMP2 2的敏感性也达到 77.8% ,明显优于细胞学的 11.3% (P <0 .0 1)。 2种方法诊断特异性分别为 79.1%和 10 0 .0 %。阳性预测值分别为 6 0 .4 %和 10 0 .0 %。结论 :NMP2 2检测是一种简单、敏感的早期诊断膀胱癌的方法。 Objective:To evaluate the diagnostic value of urinary NMP22 and cytology in the detection of bladder transitional cell carcinoma.Methods:One hundred and twenty-six sympotomatic patients suspicious of bladder cancer were asked to take urinary NMP22 and cytological examination before cytoscopy.Results:Thirty-five patients were pathologically diagnosed as transitional cell carcinoma,and 91 cases were other urological conditions.The sensitivity of NMP22 (82.9%) was significantly better than urinary cytology (25.7%) , P <0.01.For superficial bladder cancer, the sensitivity of NMP22 was also better than cytology(77.8% versus 11.3%, P <0.01).The specificity of NMP22 and cytology was 79.1% and 100.0%,with the positive predictive values 60.4% and 100.0%.Conclusions:Urinary NMP22 value is a simple ,sensitive and early diagnositic marker for bladder transitional cell carcinoma.
出处 《中国现代医学杂志》 CAS CSCD 2003年第11期10-12,共3页 China Journal of Modern Medicine
关键词 膀胱癌 尿核基质蛋白 检测方法 肿瘤标记物 Bladder Neoplasms Carcinoma Nuclear Matrix Protein
  • 相关文献

参考文献8

  • 1周辉良,罗义麒,曹林升,张声.原发性膀胱移行细胞癌Pgp与突变p53蛋白、EGFR的相互关系[J].中国现代医学杂志,2001,11(2):28-30. 被引量:10
  • 2Newling DW. Preventing recurrence and progression in superficial bladder cancer. Curt Opln Urol, 1996;6(3):272--281.
  • 3Keesee K, Brigman JV, Thill G, et al. Utilization of nuclear matrix proteins for cancer diagnosis. CRC Crit Eukaryotic Gene Exp,1996;6(2) : 189--214.
  • 4Ponsky LE, Sharma S, Pandrangi L, et al. Screaning and monitoring for bladdder cancer: Refining the use ofNMP22. J Urol, 2001;166( 1 ) :75-78.
  • 5Sanchez - carbayo M, Urrutia M, Silva JM, et al. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA21 - 1 and NMP22 for evaluating sympotomatic patients at risk for bladder Cancer. J Urol, 2001; 165(5): 1462-1467.
  • 6DelNero A, Espctsito N, Curro A, et al. Evalution of urinary level of NMP22 as a diagnostic marker for stage PTa - PT1 bledder cancer: comparison with urinary cytology and BTA test. Eur Urol,1999 ; 35(2) :93-97.
  • 7Sanchez - carbayo M, Herrero E, Meglas J, et al. Comparative sensitivity of urinary CYFRA21 - 1 ,urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. J Urol, 1999;162(6): 1951-1956.
  • 8Poulakis V, Witzsch U,Vries RD,et al. A comparison of urinary nuclear matrix protein - 22 and bladder tumor antigen tests with voided urinary cytology in detecting and following bladder cancer:the prognostic value of falm- positive results. Br J Urol,2001 ;88(7) :692 -701.

二级参考文献2

共引文献9

同被引文献36

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部